Clinical Trials
Change the model of clinical research by integrating data, expertise, analytics and technology from study design through execution to power better decisions.
-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSFEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
IQVIA AI Assistant
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Global Health
- Code of Conduct
- Sustainability
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Meet the IQVIA AI Assistant
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREIQVIA Careers
Featured Careers
Stay Connected
WE'RE HIRING
"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESWhite Paper
Objectively tracking lesions in dermatology clinical trials
Mar 04, 2019
There is an increasing need for objectivity in mapping and analyzing of lesions to create confidence in trial findings, reproducibility and translation to clinical practice for dermatology sponsors, regulators and clinicians. This paper examines evolving diagnostic practices coupled with advancing technology and their application to reduce subjectivity in dermatology clinical trials.
Learning Objectives:
IMPACT OF SKIN DISEASES
DERMATOLOGY DIVERSITY AND SUBJECTIVITY CHALLENGES
Learning Objectives:
- Learn about the challenges for objective diagnosis and evaluation of patient lesions in clinical practice and trials
- Understand the consideration of the new technologies when developing dermatology trial protocols
The diversity of dermatological illnesses, their symptoms and their causes create challenges for the objective evaluation of treatments in clinical trial settings. The expert, but subjective, physician’s global assessments of dermatological clinical practice offer limited application for capturing the consistently precise and reliable data required to define study endpoints and determine trial outcomes. When sponsors use validated disease-specific instruments for severity assessment in trial designs, they also must ensure protocols define their use and interpretation to control for subjectivity and intra- and inter-variability among investigators and trial staff. Precise tools and methods to track changes in patients’ lesions due to the effects of therapeutic interventions offer tactical approaches to institute trial standardization and quality controls. Because disease and regulatory guidelines provide limited consensus on “golden rule” instruments for assessment and monitoring, sponsors should consider the expert counsel of clinical research organizations on the adaptation and application of tools to trial settings.
This paper explores current practices as well as new technologies IQVIA™ Biotech recommends sponsors consider when developing dermatology trial protocols.
IMPACT OF SKIN DISEASES
The considerable prevalence and impact of skin diseases and disorders are anticipated to increase worldwide because of skin cancer and aging populations. In the U.S. alone, the prevalence of skin diseases is twice as high among those older than 65 years, compared to younger people,1 and the totality of skin diseases in the U.S. accounted for almost $75 billion in direct costs in 2013, a sum that comprised at least 3.8 percent of all U.S. healthcare costs.
In addition to more diagnosed patients, new medicines for melanoma and psoriasis, a strong pipeline of investigational therapies and demand for antiaging treatments are fueling growth for the dermatology sector. By 2023, the global dermatology treatment market revenues could reach $36.6 billion, at an estimated compound annual growth rate (CAGR) of 9.13 percent. Similar expansion is anticipated in the global dermatology diagnostic devices sector, which tallied $5.5 billion in 2016 with a CAGR forecast of 8.2 percent by 2024. This device market is driven by sales of tools like dermoscopes, trichoscopes, microscopes and such imaging devices as magnetic resonance imaging (MRI), ultrasound and computed tomography (CT) systems. As new imaging technologies emerge to aid in tracking and evaluating lesions, greater growth is projected.
DERMATOLOGY DIVERSITY AND SUBJECTIVITY CHALLENGES
The diversity of dermatological illnesses, as well as their symptoms and causes, creates challenges for objective diagnosis and evaluation of patients’ lesions – skin tissue abnormalities – in clinical practice and trials. Some dermatological symptoms are manifestations of disorders of the skin itself, such as the involvement of skin’s oil glands, pores and hair follicles in acne. However, the skin often is a window into a person’s inner well-being. The skin manifestations of systemic illnesses can reflect clinically significant health issues. Such diseases can be common like psoriasis or rare like scleroderma, and benign like rosacea or malignant like melanoma. Depending on the illness and a patient’s health, symptoms may range from mild to disabling. The pathogenesis of clinically meaningful changes to a person’s skin is as varied as the diseases and disorders themselves and may include infections by bacteria, viruses or mold; exposure to allergens or toxins; heritable genetic conditions; immune system disorders; and trauma.
In clinical practice, experience, visual assessment and patient’s self-reports help physicians manage all of these factors to make a diagnosis and determine the effectiveness of treatments. For dermatology trials, however, greater rigor is needed. Trial data collection should be built on objective, reproducible descriptions of the symptoms as well as the clinical signs before and after therapeutic interventions, which regulatory guidance notes should be well-defined and obtained with reliable methods.
The gold standard for evaluating investigational treatments for skin conditions is randomized and controlled trials with both investigators and participants masked from the intervention until the study’s unblinding and concluding analyses. While trial designs may differ from this standard, all must pre-specify standardized endpoints, as well as the methods to collect and assess data.
DOWNLOAD TO LEARN MORE
Related solutions
Therapeutic & Specialty Expertise
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.
Regulatory Compliance
Automate and standardize your regulatory management, from correspondence and commitments to registration and tracking.